APPA..APF530 targets a $900 million market opportunity in US alone
?Recent competitive setbacks could enhance commercial uptake
?Could be second, long-acting, injectable product on market
?In 2011, there were 5.1 million vials of injectable 5-HT3 antagonists administered for CINV
?The average selling price for market leader Aloxi is $175
APPA held end-of-review meetings with FDA in 1Q 2011
No additional clinical efficacy studies requested
News 
Market Data 
Discover 
